The CMCO strives to promote a culture of intellectual curiosity, focusing on career development and innovative approaches to science.
Center of Molecular and Cellular Oncology
The Center of Molecular and Cellular Oncology (CMCO) fosters and mentors physician-scientists as they advance their laboratory-based research programs to bridge fundamental cancer biology with clinical investigation for the translation of basic discoveries into better therapeutics, treatments or diagnosis. Physician-scientist faculty in the CMCO hold primary appointments in medical oncology or hematology at Yale Cancer Center (YCC), and participate in all divisional activities, interacting with other members of YCC. In addition, the CMCO members are part of one or more YCC Clinical Research Teams (CRTs) and YCC Research Programs relevant to their laboratory research and clinical interests, promoting a collaborative environment for the better understanding of cancer biology. As physician-scientists who spend most of their time engaged in laboratory research, interaction of CMCO members with full-time clinical colleagues promotes efficient communication of new laboratory insights into clinical trials, as well as early recognition of new clinical observations that warrant intensive laboratory investigation.
Contact Us
Yale Cancer Center Grand Rounds | January 5, 2021Markus Muschen, MD, PhD
Yale Cancer Center Grand Rounds | November 10, 2020Robbert Bona, MD and Jeffrey Ishizuka, MD, DPhil
Faculty
Arthur H. and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology; Director, Center of Molecular and Cellular Oncology; Chief, Division of Basic Science, Yale Cancer Center
EducationPhD, Institute for Genetics Cologne, 2003; MD, Heinrich-Heine-Universität Düsseldorf, 1999Assistant Professor
EducationMD, Harvard Medical School, 2013; DPhil, Oxford University, 2008; BA, Williams College, 2004Associate Professor of Internal Medicine (Medical Oncology & Hematology)
EducationMD, Harvard Medical School, 2007; PhD, Yale University, 2002Assistant Professor
EducationPhD, University of Cambridge , 2018; MSc, University of Edinburgh, 2014; MBChB, University of Edinburgh, 2010; BMedSci, University of Edinburgh, 2007Assistant Professor of Medicine (Medical Oncology), Louis Goodman and Alfred Gilman Yale Scholar
EducationMD, Icahn School of Medicine at Mount Sinai, 2013; PhD, Courant Institute of Mathematical Sciences at New York University, 2012; AB, Princeton University, 2006Assistant Professor of Medicine (Hematology)
EducationPhD, University Paris Diderot, 2013; MS, University Pierre and Marie Curie, 2009; MS, Stockholm University, 2008; BS, University of Burgundy, 2007Assistant Professor of Internal Medicine (Medical Oncology/Hematology)
EducationMD, Yale School of Medicine, 2016; PhD, Yale School of Medicine, 2015; BS, Massachusetts Institute of Technology (MIT), 2009
- May 11, 2026Source: Cancer Network
Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors
- May 07, 2026
Novel Drug Shows Promise for Treating Advanced Kidney Cancer
- April 29, 2026
Zaidi Awarded Trailblazer Cancer Research Grant
- April 23, 2026
New Research Presented from Yale Cancer Center at the AACR Annual Meeting
- April 10, 2026Source: Everyday Health (with Dr. David Braun)
Metastatic Renal Cell Carcinoma Survival Rates: What to Know
- April 03, 2026Source: Everyday Health (with Dr. David Braun)
What Treatment Options Are Available for Metastatic and Recurrent Renal Cell Carcinoma?